Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satish Keshav

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Gut|May 20, 2015
Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-upRobert V Bryant, Daniel C Burger, Joseph Delo, et al.
Plos One|March 26, 2013
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's diseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv, et al.
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|November 8, 2019
Consensus Statement by an Expert Panel on the Diagnosis and Management of Iron Deficiency Anemia in the Gulf Cooperation Council CountriesAamer Aleem, Faisal Alsayegh, Satish Keshav, et al.
Gut|January 31, 2012
A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tractsSimon J Leedham, Pedro Rodenas-Cuadrado, Kimberley Howarth, et al.
Gastroenterology|August 8, 2017
Circulating and Tissue-Resident CD4<sup>+</sup> T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During InflammationAhmed N Hegazy, Nathaniel R West, Michael J T Stubbington, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters, Yu Wang, Nu Lai, et al.
Journal of Crohn'S & Colitis|March 18, 2020
Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative ColitisStephanie M Slevin, Lucy C Garner, Conor Lahiff, et al.
Nature Medicine|April 4, 2017
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Gut|March 9, 2016
Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's diseaseTobias Schwerd, Sumeet Pandey, Huei-Ting Yang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Gut|May 20, 2015
Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-upRobert V Bryant, Daniel C Burger, Joseph Delo, et al.
Plos One|March 26, 2013
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's diseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv, et al.
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|November 8, 2019
Consensus Statement by an Expert Panel on the Diagnosis and Management of Iron Deficiency Anemia in the Gulf Cooperation Council CountriesAamer Aleem, Faisal Alsayegh, Satish Keshav, et al.
Gut|January 31, 2012
A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tractsSimon J Leedham, Pedro Rodenas-Cuadrado, Kimberley Howarth, et al.
Gastroenterology|August 8, 2017
Circulating and Tissue-Resident CD4<sup>+</sup> T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During InflammationAhmed N Hegazy, Nathaniel R West, Michael J T Stubbington, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters, Yu Wang, Nu Lai, et al.
Journal of Crohn'S & Colitis|March 18, 2020
Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative ColitisStephanie M Slevin, Lucy C Garner, Conor Lahiff, et al.
Nature Medicine|April 4, 2017
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Gut|March 9, 2016
Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's diseaseTobias Schwerd, Sumeet Pandey, Huei-Ting Yang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
Pageof 4